See more : Dr. Reddy’s Laboratories Limited (DRREDDY.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Eiger BioPharmaceuticals, Inc. (EIGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eiger BioPharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Meson Valves India Limited (MESON.BO) Income Statement Analysis – Financial Results
- Dekon Food & Agriculture Group (2419.HK) Income Statement Analysis – Financial Results
- Intapp, Inc. (INTA) Income Statement Analysis – Financial Results
- Heidelberger Druckmaschinen Aktiengesellschaft (HBGRY) Income Statement Analysis – Financial Results
- ENPLUS Co., Ltd. (074610.KS) Income Statement Analysis – Financial Results
Eiger BioPharmaceuticals, Inc. (EIGR)
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.77M | 13.48M | 12.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 24.00K | 1.84M | 745.00K | 645.00K | 486.00K | 54.00K | 41.00K | 23.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.75M | 11.65M | 11.40M | -645.00K | -486.00K | -54.00K | -41.00K | -23.00K | -11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 99.85% | 86.38% | 93.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.33M | 75.28M | 64.44M | 41.59M | 51.79M | 37.09M | 29.52M | 33.01M | 21.96M | 22.68M | 16.93M | 13.31M | 4.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.20M | 29.11M | 23.90M | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Other Expenses | 87.00K | -963.00K | 46.49M | -12.00K | -15.00K | -12.00K | 186.00K | -277.00K | 5.00K | -835.00K | 25.00K | 147.00K | 152.00K |
| Operating Expenses | 87.54M | 104.39M | 88.34M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Cost & Expenses | 87.56M | 106.22M | 89.08M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Interest Income | 2.21M | 1.08M | 158.00K | 704.00K | 2.07M | 997.00K | 410.00K | 0.00 | 65.00K | 118.00K | 69.00K | 35.00K | 7.00K |
| Interest Expense | 5.47M | 4.13M | 3.56M | 3.59M | 3.41M | 2.33M | 1.52M | 690.00K | 2.30M | 741.00K | 59.00K | 108.00K | 1.12M |
| Depreciation & Amortization | 750.00K | 119.00K | 46.65M | 1.34M | 2.54M | 54.00K | 41.00K | 23.00K | 504.00K | 153.00K | 67.00K | 64.00K | 73.00K |
| EBITDA | -68.74M | -92.62M | -76.94M | -60.81M | -66.36M | -50.06M | -40.92M | -46.40M | -33.82M | -33.02M | -19.80M | -15.70M | -5.79M |
| EBITDA Ratio | -435.81% | -686.90% | -249.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.79M | -92.74M | -76.94M | -62.15M | -68.90M | -51.05M | -41.52M | -46.12M | -42.18M | -33.02M | -19.96M | -15.95M | -6.03M |
| Operating Income Ratio | -455.12% | -687.78% | -633.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.17M | -4.01M | 43.09M | -2.90M | -1.35M | -1.34M | -928.00K | -967.00K | -2.23M | -835.00K | -127.00K | 74.00K | -965.00K |
| Income Before Tax | -74.96M | -96.75M | -33.85M | -65.05M | -70.25M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.09M | -15.87M | -6.99M |
| Income Before Tax Ratio | -475.22% | -717.54% | -278.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 6.00K | 23.00K | 64.00K | 3.58M | 3.39M | 985.00K | 1.67M | 390.00K | 2.31M | -153.00K | -12.00K | 101.00K | 1.28M |
| Net Income | -74.96M | -96.78M | -33.92M | -68.63M | -73.64M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.00M | -15.72M | -6.99M |
| Net Income Ratio | -475.26% | -717.71% | -279.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EPS Diluted | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| Weighted Avg Shares Out | 1.48M | 1.39M | 34.63M | 29.88M | 24.43M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
| Weighted Avg Shares Out (Dil) | 1.48M | 1.39M | 34.63M | 29.88M | 24.50M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Best Penny Stocks To Buy? 4 To Watch Before 2023
Penny stocks to watch before next year. The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other...
Eiger BioPharmaceuticals: A Compelling High Beta Story
Today, we revisit the investment case around Eiger BioPharmaceuticals for the first time in more than a year and a half. Eiger has one product on the market and is rapidly advancing a powerful 'sum of the parts' story.
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call Transcript
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - President and CEO Sri Ryali - Chief Financial Officer Eldon Mayer...
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger's stock falls 20% after telling investors it won't seek FDA authorization for COVID-19 drug
Shares of Eiger BioPharmaceuticals Inc. EIGR, -1.20% tumbled 20.4% in premarket trading on Wednesday after the company said it will not pursue emergency authorization of its experimental treatment for mild and moderate COVID-19 infections. It had asked the Food and...
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingrid Choong - SVP-Clinical Development Eldon Mayer - Chief Commercial...
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports